Investor Relations

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company’s precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

Upcoming Events

No events to display

Stock Information


Investor Contact


Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400

Subscribe to our Investor Alerts
* Required Fields